HRTX

Heron Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↑ 7/10
  • Momentum↓ 3/10
Heron Therapeutics sales and earnings growth
HRTX Growth
Good
  • Revenue Y/Y↑ 12.60%
  • EPS Y/Y↑ 50.00%
  • FCF Y/Y↓ -223.29%
Heron Therapeutics gross and profit margin trends
HRTX Profitability
Neutral
  • Gross margin ↑ 73.90%
  • EPS margin↓ -8.80%
  • ROIC↓ -4.50%
Heron Therapeutics net debt vs free cash flow
HRTX Risk
Poor
  • Debt / Equity↑ 9.4
  • Debt / FCF↓ 3.1
  • Interest coverage↓ -4.5

Heron Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Poor risk rating.

More Biotechnology stocks ↗